US 12,291,524 B2
Amido heteroaromatic compounds
Daniel Tor Pettersen, Södertälje (SE); Stéphanie Marcelle Gueret, Södertälje (SE); Nidhal Selmi, Södertälje (SE); Erik Lars Malmerberg, Södertälje (SE); Tord Bertil Inghardt, Södertälje (SE); Jan Åke Lindberg, Södertälje (SE); Jens Peter Brandt, Södertälje (SE); Jon Paul Janet, Södertälje (SE); and Björn Erik Anton Holm, Södertälje (SE)
Assigned to ASTRAZENECA AB, Sodertalje (SE)
Filed by AstraZeneca AB, Södertälje (SE)
Filed on Sep. 13, 2024, as Appl. No. 18/884,381.
Application 18/884,381 is a continuation of application No. 18/319,560, filed on May 18, 2023.
Claims priority of provisional application 63/383,982, filed on Nov. 16, 2022.
Claims priority of provisional application 63/367,843, filed on Jul. 7, 2022.
Claims priority of provisional application 63/364,976, filed on May 19, 2022.
Prior Publication US 2025/0011311 A1, Jan. 9, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 413/06 (2006.01); C07D 271/06 (2006.01); C07D 409/06 (2006.01); C07D 413/04 (2006.01); C07D 413/12 (2006.01); C07D 413/14 (2006.01); C07D 471/04 (2006.01); C07D 487/04 (2006.01); C07D 498/10 (2006.01)
CPC C07D 413/06 (2013.01) [C07D 271/06 (2013.01); C07D 409/06 (2013.01); C07D 413/04 (2013.01); C07D 413/12 (2013.01); C07D 413/14 (2013.01); C07D 471/04 (2013.01); C07D 487/04 (2013.01); C07D 498/10 (2013.01)] 26 Claims
 
1. A compound Formula (III):

OG Complex Work Unit Chemistry
wherein
one of X1, X2 and X3 is selected from NH, O and S and the other two of X1, X2 and X3 are independently selected from N and CRY, wherein each RY is independently H, —CN, —C(═O)N(R7)2 or RXA wherein RXA is independently C1-3 alkyl optionally substituted with one to three F;
J is selected from O, S, and a covalent bond,
x is selected from 0 to 3;
each R9 is independently selected from R3, R4 and R5;
RE is H or halo,
each R3 is independently C1-4 alkyl or C3-6 cycloalkyl, each of which are optionally substituted with one or more groups independently selected from R4X, R5x, —O(R4X), —O(R5X) and F;
each R3X is independently C1-4 alkyl or C3-6 cycloalkyl, each of which are optionally substituted with one or more F;
each R4 is independently monocyclic or bicyclic 5 to 9 membered heteroaryl, each of which are optionally substituted with one or more groups independently selected from R4X, —O(R4X), R5X, —O(R5X), —OH, —CN, C1-4 alkoxy, —C(═O) OH, —C(═O)O(C1-4 alkyl), —C(═O)N(R7B)2, R3 and halo;
each R5 is independently phenyl, each of which are optionally substituted with one or more groups independently selected from R4X, —O(R4X), R5X, —O(R5X), —OH, —CN, C1-4 alkoxy, —C(═O) OH, —C(═O)O(C1-4 alkyl), —C(═O)N(R7B)2, R3 and halo;
each R4X is independently monocyclic or bicyclic 5 to 9 membered heteroaryl, each of which are optionally substituted with one or more groups independently selected from —OH, —CN, C1-4 alkoxy, —C(═O) OH, —C(═O)N(R7B)2, R3X and halo;
each R5X is independently phenyl, each of which are optionally substituted with one or more groups independently selected from —OH, —CN, C1-4 alkoxy, —C(═O) OH, —C(═O)N(R7B)2, R3x and halo;
each R7 and R7B are independently H, C1-4 alkyl or C3-6 cycloalkyl; and
wherein each heteroaryl is independently an aromatic ring containing one or more heteroatoms independently selected from N, O and S,
or a pharmaceutically acceptable salt thereof.